loading page

Long-term response to Crizotinib in a 17-year-old boy with naive alk-positive Non-Small Cell Lung Cancer
  • +10
  • giacomina megaro,
  • Evelina Miele,
  • Gian Paolo Spinelli,
  • Iside Alessi,
  • Giada Del Baldo,
  • Raffaele Cozza,
  • Ida Russo,
  • Maria Debora De Pasquale,
  • Maria Giuseppina Cefalo,
  • Paolo Toma,
  • Valentina Di Ruscio,
  • Maria Antonietta De Ioris,
  • Angela Mastronuzzi
giacomina megaro
Ospedale Pediatrico Bambino Gesù
Author Profile
Evelina Miele
Ospedale Pediatrico Bambino Gesu
Author Profile
Gian Paolo Spinelli
UOC Oncologia Universitaria, ASL Latina (distretto Aprilia), Sapienza University of Rome
Author Profile
Iside Alessi
Bambino Gesu Pediatric Hospital
Author Profile
Giada Del Baldo
Bambino Gesu Pediatric Hospital
Author Profile
Raffaele Cozza
Bambino Gesu Pediatric Hospital
Author Profile
Ida Russo
Ospedale Pediatrico Bambino Gesu
Author Profile
Maria Debora De Pasquale
Bambino Gesu Pediatric Hospital
Author Profile
Maria Giuseppina Cefalo
Bambino Gesu Pediatric Hospital
Author Profile
Paolo Toma
Bambino Gesù Children's Research Hospitals
Author Profile
Valentina Di Ruscio
Bambino Gesù Pediatric Hospital
Author Profile
Maria Antonietta De Ioris
Ospedale Pediatrico Bambino Gesù
Author Profile
Angela Mastronuzzi
Bambino Gesu Pediatric Hospital
Author Profile

Abstract

Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In younger patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrange-ment of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by FDA. We present the case of a 17-year-old male with metastatic naïve ALK-positive adenocarcinoma, treated with crizotinib. He received crizotinib and obtained a prolonged response with PFS of 33 months. Crizotinib can be extremely effective in adolescent with naïve ALK-positive NSCLC but it hardly penetrates blood-brain barrier. Resistance mechanisms will be investigated for a better man-agement.